Despite increased efficacy of regimens combining cytotoxic drugs and targeted agents, most patients with metastatic colorectal cancer will ultimately die of the disease. Only a limited number of drugs have reproducible activity in therapy of this tumor, and new active agents are urgently needed. Promising results in the therapy of metastatic colorectal cancer have been reported for patupilone, an epothilone analogue. Similarly to taxanes, the cytotoxic mechanism of epothilones involves the stabilization of microtubules. Increased serum or urinary concentrations of neopterin have been described in patients with tumors of different primary locations, including colorectal cancer. Neopterin concentrations were reported to increase during the administration of cytotoxic agents, including taxane-based chemotherapy. We have studied serum neopterin in patients with colorectal cancer before and during the therapy with patupilone. Urinary neopterin/creatinine concentrations were determined with highperformance liquid chromatography. Increased urinary neopterin concentrations were observed at baseline in the majority of the patients. In most patients, neopterin concentrations further increased during the therapy, and a significant increase of urinary neopterin was observed in patients with normal baseline neopterin concentrations. A trend of decreased survival was observed for patients with high initial neopterin concentration. In conclusion, urinary neopterin is increased in colorectal cancer patients presenting for second or higher line of treatment. An increase of urinary neopterin during patupilone therapy suggests an activation of immune response by this agent.
Introduction
Colorectal carcinoma is one of the most frequent malignant tumors and also one of the leading causes of mortality for cancer. An overwhelming majority of colorectal carcinoma deaths is caused by uncontrolled growth of metastases. Chemotherapy is the principal therapeutic modality in patients with metastatic colorectal carcinoma. The last 15 years have witnessed considerable progress in the chemotherapy of colorectal carcinoma. After demonstration that fluoropyrimidine-based chemotherapy significantly prolongs survival in patients with metastatic colorectal carcinoma, two new active agents, irinotecan and oxaliplatin, have been introduced (1) , and further incremental survival gains have been demonstrated for the combination of fluoropyrimidines with these agents, or, more recently, with targeted agents (2, 3) . Currently, five agents or classes of drugs with different mechanism of action are available for the therapy of metastatic colorectal carcinoma, including fluoropyrimidines (i.e. 5-fluorouracil and capecitabine), irinotecan, oxaliplatin, bevacizumab and the monoclonal antibodies targeting epidermal growth factor receptor (cetuximab and panitumumab). Unfortunately, these agents or their combinations are rarely curative in the setting of metastatic disease, and, in almost all patients initially responding to the therapy, the disease will eventually progress. Non-cross resistant anticancer drugs are urgently needed as therapeutic options using available agents or their combi-nations will ultimately be exhausted during the course of the disease in individual patients.
Encouraging data have been reported regarding the efficacy of patupilone in the therapy of metastatic colorectal carcinoma (4) . Patupilone, an epothilone analogue, is a novel microtubule-stabilizing agent that induces cell cycle arrest and apoptosis. Patupilone has a peculiar toxicity profile with little or no hematologic toxicity, limited neurotoxicity, but significant gastrointestinal side effects, mostly diarrhea.
The mechanism of action of patupilone is similar to taxanes and involves the stabilization of microtubules. After administration of taxanes, activation of systemic immune and inflammatory response reflected in increased serum concentrations of pro-inflammatory cytokines (5, 6) or increased urinary neopterin (7) has been reported. Moreover, increased serum levels of pro-inflammatory cytokines have been associated with flu-like symptoms and fatigue accompanying paclitaxel administration (5) .
A significant problem associated with measuring serum or plasma cytokine concentrations are sometimes marked fluctuations of systemic cytokine concentrations even within a short time frame. Neopterin is a pteridine produced from guanosine triphosphate (GTP) by activated macrophages in a reaction catalyzed by the enzyme GTP cyclohydrolase I. The activity of GTP cyclohydrolase I is induced by interferon-γ (IFN-γ) produced by T-lymphocytes and natural killer cells, and serum concentrations of this cytokine are reflective of systemic immune response. However, the production of IFN-γ is enhanced by proinflammatory cytokines, such as interleukin-1 or interleukin-6. The pro-inflammatory cytokines are known to enhance or, to a lesser degree, induce neopterin production. Thus, systemic concentrations of neopterin reflect both systemic immune and inflammatory response (8) . Neopterin may be measured in serum or in urine, and both serum and urinary neopterin concentrations have been validated as indicators of systemic immune and inflammatory response in disorders ranging from cancer to viral infections, transplant rejection, or atherosclerosis.
There are currently no data on the activation of systemic immune response in patients treated with patupilone. In the present study, we evaluated urine neopterin/creatinine concentrations in patients with metastatic colon cancer treated with patupilone in a phase I clinical trial.
Material and Methods
Seventeen patients, 8 males and 9 females, aged (mean ± standard deviation) 64 ± 8 (range 50 -74) years, with metastatic colorectal cancer progressing after at least one line of therapy for metastatic disease enrolled in a phase I trial of patupilone at Charles University Medical School Teaching Hospital in Hradec Králové, Czech Republic were studied.
Patupilone was administered every 3 weeks either as bolus (20 min), 1-day continuous infusion (24 hours; CIV-1D) or 5-day continuous infusion (16-hours per day over 5 days; CIV-5D) with planned dose levels of 6.5, 7.0, 8.0, 9.0, 10.0 mg/m 2 until disease progression, unacceptable toxicity or withdrawal of consent. The toxicity was assessed using Common Terminology Criteria for Adverse Events version 3.0 (http://ctep.cancer.gov). Serious toxicity was defined as of grade 3 or higher.
Urinary neopterin was determined as described (9) . Briefly, urine sample were collected and stored at -20°C until analysis. After centrifugation (5 minutes, 1300 g) and diluting 100 µl of urine specimens with 1.0 ml of mobile phase containing 2 g of disodium-EDTA per liter, samples were injected onto a column, and neopterin was determined using high performance liquid chromatography system Prominence LC20 (Shimadzu, Kyoto, Japan). Neopterin was identified by its native fluorescence (353 nm excitation, 438 nm emission) and quantified by external standard method. Creatinine was determined by Jaffé reaction after dilution of the sample 1:50 on a Modular analyzer (Roche, Basel, Switzerland) using a commercial kit according the manufacturer's instructions, and neopterin concentrations were expressed as neopterin/creatinine ratio (µmol/mol creatinine).
Neopterin concentrations before and during the treatment was compared by Wilcoxon signed rank test. Differences among groups of patients were studied using Mann-Whitney U test. Survival was analyzed using the Kaplan-Meier method, and differences were evaluated by log-rank test. The decision on statistical significance was based on p = 0.05 level. The analyses were performed using NCSS software (Number Cruncher Statistical Systems, Kaysville, UT, USA).
Results
Mean baseline neopterin in the 17 patients evaluated was 297 ± 188 (range 42 -686) µmol/mol creatinine. Baseline urinary neopterin was increased above the threshold of 214 µmol/mol creatinine (defined in an earlier study (9)) in 9 out of 17 patients with metastatic colon cancer. In most patients, neopterin concentrations further increased during the therapy with patupilone. In 9 patients, two measurements were obtained before the start of treatment, 10 ± 4 (range 7 -18) days apart (at screening and immediately before the administration of the first dose). Urinary neopterin was significantly increased at the second pre-treatment measurement (417 ± 258 µmol/mol creatinine) compared to baseline (333 ± 211 µmol/mol creatinine; p < 0.05; Figure 1 ). Sixteen patients had at least one neopterin measurement during the first course of therapy. The peak urinary neopterin concentration during the first cycle was observed 9 ± 4 (range 3 -14) days after the start of treatment (416 ± 240 µmol/mol creatinine) and was only non-significantly higher compared to highest pre-treatment value (353 ± 230 µmol/mol creatinine).
Among the 8 patients with baseline neopterin below 214 µmol/mol creatinine, pre-therapeutic urinary neopterin concentrations (i.e. urinary neopterin concentrations at screening and before administration of the first cycle) were stable, with the exception of a pretherapeutic increase above 214 µmol/mol creatinine that was observed in one patient in association with an episode of diarrhea (from 161 to 428 µmol/mol creatinine). In the remaining patients, at least one measurement was obtained during the first cycle in 6 cases. An increase of urinary neopterin was observed in all these patients (from highest pre-treatment value of 136 ± 62 µmol/mol creatinine to a peak of 213 ± 138 µmol/mol creatinine, p < 0.05).
A trend of decreased survival was observed for patients with initial neopterin concentration above 214 µmol/mol creatinine (median survival 25 vs. 11 months, p = 0.13; Figure 3 ). Baseline neopterin concentrations were not significantly different in patients who subsequently did or did not experience gastrointestinal toxicity (385 ± 269 vs. 346 ± 232 µmol/mol creatinine) or any grade 3 toxicity (401 ± 331 vs. 332 ± 184 µmol/mol creatinine).
Discussion
Baseline urinary neopterin was increased in most patients with metastatic colorectal cancer treated evaluated in this clinical trial with patupilone that was administered as second or higher line of therapy. The high prevalence of increased neopterin levels corresponds to the advanced disease progressing after previous therapy in most patients. Rapidly progressive disease was also reflected in significantly rising neopterin during pre-treatment evaluation. Present data demonstrate a further increase of neopterin during therapy with patupilone that was observed in most patients studied. This increase was significant in patient with baseline neopterin in the normal range. This observation indicates that patupilone may induce systemic immune activation. However, because of limited number of patients included in the present investigation the results have to be regarded as exploratory. Moreover, difference schedules on patupilone administrations have been used in the present group of patients. In future studies, the effect of patupilone on systemic immune activation should be assessed on a larger patient cohort. An increase in serum or urinary neopterin concentrations in cancer patients has been amply documented (10, 11) . In patients with tumors of different primary locations, increased serum or urinary neopterin concentrations were associated with poor prognosis (10, 11) . The number of patients in the present study limited the power to investigate the prognostic significance of increased neopterin concentrations, but a trend of an association between higher neopterin and poor prognosis was evident. An increase of urinary neopterin concentrations has been demonstrated during administration of various anticancer drugs including cytokines (10) or different cytotoxic drugs (12), but nothing was previously known about neopterin in patients treated with patupilone or other epothilone analogues. Immunomodulatory action has been documented for taxanes, a class of anticancer agents that have a mechanism of action similar to epothilones (13) (14) (15) . The immunomodulatory effects of taxanes, e.g. paclitaxel, observed in experimental studies included stimulation of cytokine production, e.g. interleukin-1, tumor necrosis factor-α or interleukin-12 (13) (14) (15) . In earlier studies, increased urinary neopterin concentrations were observed during the therapy with paclitaxel either in combination with doxorubicin (12) or administered as weekly monotherapy (7) . Present data extend the spectrum of cytotoxic agents with possible immunostimulatory effect to epothilones.
In conclusion, urinary neopterin is increased in most patients presenting for second or higher line of therapy of metastatic colon cancer. An increase in urinary neopterin was observed in most patients treated with patupilone in the present cohort, suggesting the activation of the immune system by the drug. A trend of poor survival was evident in patients with high baseline neopterin concentrations.
